Steven Targum, M.D. — Scientific Director

Steve Targum
As the Founder and Scientific Director of Clintara, Dr. Targum consults widely to the pharmaceutical industry regarding the design and implementation of clinical trials for new psychotropic drugs and the progression of drug development from concept to approval to launch. In addition to his work at Clintara, Dr. Targum is a Chief Medical Advisor at Prana Biotechnology Ltd. and has served as Chief Medical Officer at several small biotechnology and pharmaceutical companies.

In 1991, Dr. Targum established and operated a multi-site clinical trials program in Philadelphia. As Principal Investigator, he conducted over 200 clinical drug trials in therapeutic areas that included anxiety, depression, mania, schizophrenia, and Alzheimer’s disease.

In 2001, Dr. Targum founded PharmaStar, a rater training and medical education company focused on CNS drug development and international clinical trials. The company grew quickly and became the global leader in this niche when it was sold in October 2004 to United BioSource Corporation.

Previously, He was Professor of Psychiatry and Vice-Chairman of the Department of Mental Health Sciences at Hahnemann University School of Medicine (Philadelphia) from 1989-1995. He has published over 100 scientific articles in the areas of psychopharmacology, psychobiology, and clinical trials methodology.

Dr. Targum has a B.A. in biology from Colgate University and an M.D. from Mount Sinai School of Medicine.

View Dr. Targum’s complete CV

Colin Bower, MBA — President and CEO

Colin Bower

Mr. Bower brings extensive business consulting and senior executive experience, having managed and driven substantial growth of public and private companies on a global scale. Colin led Arthur Andersen’s multi-million dollar global capital markets practice, providing advisory, strategy and transaction services to multinational clients and sovereign entities across EMEA and APAC.

Prior to joining Andersen, Colin was a US Presidential Appointee at the US Department of the Treasury. Upon leaving Andersen, Colin successfully managed and grew high growth companies to capital events, and was the founder and general partner of a private equity fund.

Colin has a BA from McGill University, an MBA from the University of Chicago Booth School of Business, and a Certificate in Advanced Corporate Finance from INSEAD, France.

Philip Rauh, MA, — Chief Operating Officer

Philip Rauh

Philip Rauh holds a MA of International Economics with emphasis on quantitative analysis from the Graduate Institute of International Studies of the University of Geneva in Switzerland. He has spent most of his career in the financial service industry and has worked in various European countries as well as the US and Canada. He held various leading roles in the areas of data analysis, client management and process implementation.

Philip recently joined Clintara from a Boston based private equity boutique where he was responsible for global client and sales management and a member of the executive board. At Clintara Philip oversees client services with a focus on product and service delivery and quality control.

Cara Pendergrass, Ph.D. — Vice President, Clinical Operations

Cara Pendergrass

Dr. Pendergrass has extensive experience in developing and executing comprehensive clinical studies involving various psychiatric populations, including schizophrenia, bipolar disorder, depression, and dementia in addition to specialty training in clinical neuropsychology and neuroimaging.

Her expertise in multiple methodologies, including a wide range of clinical interviews, questionnaires, neuropsychological evaluations, cognitive neuroscience tasks, and neuroimaging, affords her the opportunity to better conduct translational research and examine different mechanisms that contribute to the development, maintenance, and worsening of clinical and cognitive symptoms in psychiatric disorders, which ultimately may be targets for treatment and/or psychotherapeutic intervention.

In 2003, Dr. Pendergrass received an Early Career Investigator Award from the College on Problems of Drug Dependence and a Junior Investigator Travel Award from the National Institute on Drug Abuse (NIDA).

As a fellow at Dartmouth Medical School, Dr. Pendergrass contributed to the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a multisite longitudinal clinical/imaging/genetic biomarker study with the goals of defining the progression of Alzheimer’s Disease, identification of biomarkers, and the discovery and development of treatments.

Dr. Pendergrass also maintains her clinical license as a psychologist with a specialty in Neuropsychology. She is scheduled to complete her Board Certification in Clinical Neuropsychology in the Fall of 2012. She has worked extensively with severe and chronically mentally ill, geriatric, medically ill, and neurological patient populations. She also has specialty training in treating Obsessive Compulsive Disorder and Posttraumatic Stress Disorder.

Dr. Pendergrass graduated with a B.A. in Psychology with Honors from Vanderbilt University and obtained an M.S. and Ph.D. in Clinical Psychology with a specialization in Neuropsychology from Rosalind Franklin University of Medicine and Science. She completed her internship and post-doctoral fellowship in Clinical Neuropsychology at the University of Illinois-Chicago and Dartmouth Medical School, respectively.